Add-on effects of valsartan on morbi-mortality in high risk hypertension
Phase of Trial: Phase IV
Latest Information Update: 11 Dec 2012
At a glance
- Drugs Valsartan (Primary)
- Indications Cardiovascular disorders; Essential hypertension
- Focus Biomarker; Therapeutic Use
- Acronyms KHS; KYOTO-HEART
- 31 Aug 2018 Biomarkers information updated
- 11 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2011 Results of an analysis that focused on the effect of renal function on treatment outcomes presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.